Department of Pediatrics and Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center in Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063, USA.
Immunol Allergy Clin North Am. 2010 Feb;30(1):1-15. doi: 10.1016/j.iac.2009.11.005.
The last 40 years has seen the emergence of hematopoietic stem cell transplantation as a therapeutic modality for fatal diseases and as a curative option for individuals born with inherited disorders that carry limited life expectancy and poor quality of life. Despite the rarity of many primary immunodeficiency diseases, these disorders have led the way toward innovative therapies and further provide insights into mechanisms of immunologic reconstitution applicable to all hematopoietic stem cell transplants. This article represents a historical perspective of the early investigators and their contributions. It also reviews the parallel work that oncologists and immunologists have undertaken to treat both primary immunodeficiencies and hematologic malignancies.
过去的 40 年见证了造血干细胞移植作为治疗致命疾病的一种治疗方式的出现，也为那些出生时就患有遗传性疾病的人提供了一种治愈的选择，这些疾病的预期寿命有限，生活质量也很差。尽管许多原发性免疫缺陷疾病都很罕见，但这些疾病为创新疗法开辟了道路，并进一步深入了解了适用于所有造血干细胞移植的免疫重建机制。本文代表了早期研究人员及其贡献的历史视角。它还回顾了肿瘤学家和免疫学家为治疗原发性免疫缺陷和血液系统恶性肿瘤所做的并行工作。
